Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vistagen Therapeutics (VTGN) Enterprise Value (2016 - 2025)

Vistagen Therapeutics' Enterprise Value history spans 13 years, with the latest figure at -$61.8 million for Q4 2025.

  • For Q4 2025, Enterprise Value rose 30.25% year-over-year to -$61.8 million; the TTM value through Dec 2025 reached -$61.8 million, up 30.25%, while the annual FY2025 figure was -$80.5 million, 32.46% up from the prior year.
  • Enterprise Value for Q4 2025 was -$61.8 million at Vistagen Therapeutics, up from -$77.2 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$9.6 million in Q2 2023 and bottomed at -$126.6 million in Q4 2023.
  • The 4-year median for Enterprise Value is -$88.6 million (2024), against an average of -$83.2 million.
  • The largest annual shift saw Enterprise Value tumbled 7508.91% in 2021 before it soared 41.7% in 2025.
  • A 4-year view of Enterprise Value shows it stood at -$83.7 million in 2021, then plummeted by 51.21% to -$126.6 million in 2023, then surged by 30.02% to -$88.6 million in 2024, then skyrocketed by 30.25% to -$61.8 million in 2025.
  • Per Business Quant, the three most recent readings for VTGN's Enterprise Value are -$61.8 million (Q4 2025), -$77.2 million (Q3 2025), and -$63.2 million (Q2 2025).